Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02949219 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
A Phase 2 study of Metastatic Small Intestinal Adenocarcinoma and Recurrent Small Intestinal Carcinoma, sponsored by Academic and Community Cancer Research United.
- Active
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 8
- Study locations
NCT02949219: Active Phase 2 study of Metastatic Small Intestinal Adenocarcinoma and Recurrent Small Intestinal Carcinoma, sponsored by Academic and Community Cancer Research United.
NCT02949219 is a Phase 2 study of Metastatic Small Intestinal Adenocarcinoma and Recurrent Small Intestinal Carcinoma that is active but no longer recruiting, run by Academic and Community Cancer Research United. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02949219, a Phase 2 study of Metastatic Small Intestinal Adenocarcinoma and Recurrent Small Intestinal Carcinoma, is active but no longer recruiting, sponsored by Academic and Community Cancer Research United.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 8
- Study locations
Study Summary
This phase II trial studies how well pembrolizumab works in treating patients with small bowel adenocarcinoma that has spread to other places in the body or that cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
Study Locations (8)
Arizona
- Mayo Clinic Hospital - Phoenix
- Mayo Clinic in Arizona - Scottsdale
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University School of Medicine - St Louis
New York
- Roswell Park Cancer Institute - Buffalo
South Dakota
- Rapid City Regional Hospital - Rapid City
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2017-03-24 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 2 |
What the registry record for NCT02949219 still lists
NCT02949219 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 3 conditions, with Metastatic Small Intestinal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02949219 lists 8 locations in 7 states (Arizona, District of Columbia, Minnesota).
Frequently Asked Questions
What is clinical trial NCT02949219 about?
NCT02949219 is a clinical study titled "Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery". This phase II trial studies how well pembrolizumab works in treating patients with small bowel adenocarcinoma that has spread to other places in the body or that cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spre...
What is the current status of trial NCT02949219?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2017-03-24. Estimated completion is 2024-12-31.
What conditions does trial NCT02949219 study?
This clinical trial studies the following conditions: Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal Carcinoma.
What interventions are being tested in trial NCT02949219?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02949219?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02949219 being conducted?
This trial has 8 study locations across Arizona, District of Columbia, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Small Intestinal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02949219's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI